Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Abstract Introduction Evidence for dual antidiabetic therapy in type 2 diabetes mellitus patients with cirrhosis is limited. This study compared 5-year mortality, composite hepatic decompensation risk, and hepatocellular carcinoma occurrence in patients with diabetes and cirrhosis who were either on...

Full description

Bibliographic Details
Main Authors: Daniel J Huynh, Benjamin D Renelus, Daniel S Jamorabo
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Gastroenterology
Subjects:
Cirrhosis
Diabetes mellitus
Metformin
Sodium-glucose co-transporter-2 inhibitors
Mortality
Hepatic decompensation
Online Access:https://doi.org/10.1186/s12876-023-03085-8

Internet

https://doi.org/10.1186/s12876-023-03085-8

Similar Items